News | Stroke | February 16, 2023

Percent Insular Ribbon Infarction for Growth Rate Prediction, Outcomes in Large-Vessel Occlusive Stroke

Acute ischemic stroke patients with each PIRI score on 5-point scale

February 16, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), percent insular ribbon infarction (PIRI) complements current stroke outcome predictors, classifying patients with slowly progressive stroke who could benefit from late-window endovascular thrombectomy (EVT).

Noting that PIRI was independently associated with infarct growth rate and 90-day outcome, “PIRI may help identify patients who could benefit from late-window EVT when requiring transfer to EVT-capable centers,” wrote head researcher Robert W. Regenhardt, MD, PhD, from the department of neurology at Massachusetts General Hospital and Harvard Medical School.

Analyzing a previous clinical trial of acute stroke patients untreated with reperfusion therapies from January 2007 to June 2009, Regenhardt et al. reevaluated 31 trial patients (median age, 71 years; 12 female, 19 male) with anterior-circulation large-vessel occlusion who underwent serial MRI examinations. Two neuroradiologists independently scored PIRI on presentation MRI—mild (0-1), moderate (2), severe (3-4)—based upon length ratios of the insula portion showing restricted diffusion to the insula’s total length. A 90-day modified Rankin Scale (mRS) was also obtained.

Ultimately, in multivariable models controlling for age, large-vessel occlusion location, and collateral pattern, PIRI category was a significant independent predictor of presentation-to-48-hour infarct growth rate (β=1.3) and 90-day mRS ≤2 (OR=0.2). Sensitivity and specificity for predicting 90-day mRS ≤2 were 90% and 84% for mild-to-moderate PIRI, versus 70% and 74% for symmetric collateral pattern.

“To our knowledge,” the authors of this AJR accepted manuscript added, “the present study is the first to show the PIRI category to be an independent predictor of 90-day mRS <2 in multivariable models.”

For more information: www.arrs.org


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now